List of works - Mathias Witzens-Harig

A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse la

scientific article

HTLV-1-associated adult T cell leukemia is highly susceptible to Navitoclax due to enhanced Bax expression

scientific article

Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

scientific article

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting.

scientific article

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

scientific article published on 04 December 2015

Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells

scientific article

Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells

scientific article published in January 2007

Mild bleeding diathesis in a 62-year-old woman with hereditary thrombocytopenia

scientific article

Performance assessment and benchmarking of autologous peripheral blood stem cell collection with two different apheresis devices

scientific article

Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy ⬇️

scientific article published on September 21, 2010

Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma

scientific article

Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial.

scientific article published on 9 October 2015

Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma

scientific article

Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma

scientific article published on 8 November 2012

The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma

scientific article

The impact of high-dose chemotherapy, autologous stem cell transplant and conventional chemotherapy on quality of life of long-term survivors with follicular lymphoma

scientific article published on 10 October 2011

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas.

scientific article

Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial

scientific article

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies

scientific article

List of works by Mathias Witzens-Harig

A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse la

HTLV-1-associated adult T cell leukemia is highly susceptible to Navitoclax due to enhanced Bax expression

Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting.

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells

Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells

Mild bleeding diathesis in a 62-year-old woman with hereditary thrombocytopenia

Performance assessment and benchmarking of autologous peripheral blood stem cell collection with two different apheresis devices

Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy ⬇️

Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma

Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial.

Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma

Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma

The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma

The impact of high-dose chemotherapy, autologous stem cell transplant and conventional chemotherapy on quality of life of long-term survivors with follicular lymphoma

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas.

Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies